University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

KaliVir Immunotherapeutics

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Oncology

Funding Stage

Series A+

Founders

Stephen Thorne

Website

https://www.kalivir.com

KaliVir Immunotherapeutics is developing next-generation oncolytic viral immunotherapies for cancer. Its Vaccinia Enhanced Template (VET) platform engineers vaccinia viruses that can be delivered intravenously, replicate selectively in tumors, and express therapeutic payloads. [1]

The company was co-founded in 2019 by Stephen Thorne, a former University of Pittsburgh professor of cell biology and immunology who serves as chief scientific officer. In August 2026 it announced the closing of a $14 million Series A extension, and it has a clinical trial collaboration and supply agreement with Roche. [1] [2]

Discover More with AI